Sponsors (4)
Official title: To direct the Secretary of Defense to submit to Congress a report on emerging investigational treatment options for treatment-resistant post-traumatic stress disorder in veterans, members of the Armed Forces, and members transitioning to civilian life, and for other purposes.
Introduced June 30, 2026 by Abraham J. Hamadeh · Last progress June 30, 2026
The bill directs DoD to study and report on potential psilocybin access for service members—potentially expanding treatment options and creating interagency oversight—while posing significant unknown health/readiness risks, legal and privacy concerns, and additional costs if access is pursued without full regulatory approvals.
Servicemembers with treatment‑resistant PTSD (and other military patients) could gain a pathway to access psilocybin‑based therapy, potentially providing a new option when existing treatments have failed.
A required DoD report would gather safety, dosing, and adverse‑event data and drive interagency coordination (DoD, VA, HHS, FDA, DEA), establishing oversight and aligned standards before any pilot or program is launched.
Assessing continuity of care between DoD and VA could improve transition‑period treatment, monitoring, and follow‑up for veterans who receive investigational therapies.
Servicemembers could be exposed to unknown medical risks and adverse events from an investigational Schedule I drug (psilocybin), including harms that are not yet well characterized.
Acute side effects or the need for monitoring could reduce medical readiness and operational capability for deployed or high‑readiness units.
Relying on Right‑to‑Try or expedited executive pathways risks bypassing full FDA approval, creating legal, liability, and standards‑of‑care uncertainties for patients and the departments.
Based on analysis of 2 sections of legislative text.
Requires DoD to report within 180 days on safety, operational relevance, legal pathways, continuity of care, and resource needs for applying a 2026 psilocybin PTSD trial to Armed Forces personnel.
Requires the Assistant Secretary of Defense for Health Affairs to prepare and deliver a report within 180 days evaluating whether data from a 2026 clinical trial of whole‑mushroom psilocybin for PTSD are operationally relevant and safe for use with Armed Forces personnel. The report must summarize safety, dosing, and adverse events; assess force health protection, medical readiness, and suicide prevention implications; describe legal/regulatory pathways (FDA/DEA coordination and applicability of Federal Right to Try and Executive Order No. 14401); evaluate continuity of care from military to VA; and outline workforce, infrastructure, costs, and a timeline for pilots or expanded research starting FY2027.